Idursulfase

Idursulfase (brand name Elaprase), manufactured by Shire, is a drug used to treat Hunter syndrome (also called MPS-II).[1] It is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced by recombinant DNA technology in a human cell line.

Idursulfase
Clinical data
AHFS/Drugs.comMonograph
License data
ATC code
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
 NY (what is this?)  (verify)

It is one of the most expensive drugs ever produced, costing US$567,412 per patient per year.[2][3][4]

References
  1. Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC (2007). "Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II". Mol. Genet. Metab. 91 (2): 183–90. doi:10.1016/j.ymgme.2007.03.003. PMID 17459751.
  2. "Drug approved to treat rare but potentially deadly disease". Retrieved 2011-04-29.
  3. Health Care: The World's Most Expensive Drugs, Matthew Herper, Forbes, Feb. 22, 2010
  4. , Barbara Kollmeyer, Marketwatch, Fed. 3, 2016
  • idursulfase at the US National Library of Medicine Medical Subject Headings (MeSH)


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.